Delivery strategies and potential targets for siRNA in major cancer types

So Jin Lee, Min Ju Kim, Ick Chan Kwon, Thomas M. Roberts

Research output: Contribution to journalReview articlepeer-review

101 Citations (Scopus)


Small interfering RNA (siRNA) has gained attention as a potential therapeutic reagent due to its ability to inhibit specific genes in many genetic diseases. For many years, studies of siRNA have progressively advanced toward novel treatment strategies against cancer. Cancer is caused by various mutations in hundreds of genes including both proto-oncogenes and tumor suppressor genes. In order to develop siRNAs as therapeutic agents for cancer treatment, delivery strategies for siRNA must be carefully designed and potential gene targets carefully selected for optimal anti-cancer effects. In this review, various modifications and delivery strategies for siRNA delivery are discussed. In addition, we present current thinking on target gene selection in major tumor types.

Original languageEnglish
Pages (from-to)2-15
Number of pages14
JournalAdvanced Drug Delivery Reviews
Publication statusPublished - 2016

Bibliographical note

Funding Information:
This study was supported by Global Innovative Research Center (GiRC) project (2012K1A1A2A01055811) of the National Research Foundation of Korea, the Intramural Research Program (Global RNAi Carrier Initiative) of KIST, and a grant from the Women's Cancers Program of Dana-Farber Cancer Institute.

Publisher Copyright:
© 2016 Elsevier B.V.


  • Cancer
  • Delivery strategy of siRNAs
  • Gene target
  • Small interfering RNA (siRNA)
  • siRNA therapeutics

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Delivery strategies and potential targets for siRNA in major cancer types'. Together they form a unique fingerprint.

Cite this